Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses the DREAMM-7 (NCT04246047) and DREAMM-8 (NCT04484623) trials, which have established belantamab mafodotin combinations as a potential new second-line standard of care (SoC) for multiple myeloma (MM). DREAMM-7 demonstrated the efficacy of belantamab mafodotin with bortezomib and dexamethasone, while DREAMM-8 showed its efficacy with pomalidomide and dexamethasone. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
